guanidine has been researched along with Breast Cancer in 4 studies
Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.
guanidine : An aminocarboxamidine, the parent compound of the guanidines.
| Excerpt | Relevance | Reference |
|---|---|---|
| " For this purpose, guanidine functionalized PEGylated I3ad mesoporous silica nanoparticle KIT-6 [Gu@PEGylated KIT-6] was utilized as a promising system for the effective delivery of curcumin into the breast cancer cells." | 7.80 | Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: practical strategy for the breast cancer therapy. ( Al-Musawi, S; Askarlou, S; Foroumadi, A; Kheiri-Manjili, H; Ma'mani, L; Nikzad, S; Saeedi, M; Shafiee, A, 2014) |
| " For this purpose, guanidine functionalized PEGylated I3ad mesoporous silica nanoparticle KIT-6 [Gu@PEGylated KIT-6] was utilized as a promising system for the effective delivery of curcumin into the breast cancer cells." | 3.80 | Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: practical strategy for the breast cancer therapy. ( Al-Musawi, S; Askarlou, S; Foroumadi, A; Kheiri-Manjili, H; Ma'mani, L; Nikzad, S; Saeedi, M; Shafiee, A, 2014) |
| "Carriers of germ line mutations in breast cancer susceptibility gene BRCA1 have an increased risk of developing breast and ovarian cancers; missense mutations have, however, been difficult to assess for disease association." | 1.36 | Toward classification of BRCA1 missense variants using a biophysical approach. ( Cook, R; Itzhaki, LS; Rowling, PJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pruszynski, M | 1 |
| Koumarianou, E | 1 |
| Vaidyanathan, G | 2 |
| Revets, H | 1 |
| Devoogdt, N | 1 |
| Lahoutte, T | 1 |
| Lyerly, HK | 1 |
| Zalutsky, MR | 2 |
| Ma'mani, L | 1 |
| Nikzad, S | 1 |
| Kheiri-Manjili, H | 1 |
| Al-Musawi, S | 1 |
| Saeedi, M | 1 |
| Askarlou, S | 1 |
| Foroumadi, A | 1 |
| Shafiee, A | 1 |
| Jestin, E | 1 |
| Olafsen, T | 1 |
| Wu, AM | 1 |
| Rowling, PJ | 1 |
| Cook, R | 1 |
| Itzhaki, LS | 1 |
4 other studies available for guanidine and Breast Cancer
| Article | Year |
|---|---|
Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzoates; Breast Neoplasms; Fema | 2014 |
Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: practical strategy for the breast cancer therapy.
Topics: Animals; Apoptosis; Biological Transport; Breast Neoplasms; Curcumin; Drug Carriers; Guanidine; Huma | 2014 |
Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
Topics: Animals; Antibodies, Monoclonal; Benzoates; Biological Transport; Breast Neoplasms; Cell Line, Tumor | 2009 |
Toward classification of BRCA1 missense variants using a biophysical approach.
Topics: Algorithms; Binding Sites; BRCA1 Protein; Breast Neoplasms; Escherichia coli; Female; Fluorescence P | 2010 |